首页> 中文期刊>中国生化药物杂志 >抗多发性骨髓瘤的STAT3抑制剂及其研究策略

抗多发性骨髓瘤的STAT3抑制剂及其研究策略

     

摘要

STAT3是重要的基因转录调控因子,能将细胞表面受体产生的信号转导至细胞核内,并在核内与特异性的DNA序列结合从而调控基因的表达。 STAT3分布广泛,除了参与正常细胞的生命活动之外,还与炎症和肿瘤的发生关系密切。 STAT3是多种肿瘤的治疗靶标,一系列STAT3抑制剂已经被报道。本文重点回顾和展望了STAT3信号通路与多发性骨髓瘤发生的关系以及STAT3靶向药物研究进展和研究策略。%The STAT3 protein is a key transcription factor that delivers extracellular signals into nuclei in which it binds to a specific recognition element on DNA sequences and thus regulates the transcription of its target genes.STAT3 is almost expressed in all tissues and cells, therefore, it is extensively involved in both normal and aberrant cellular activities.For example, STAT3 plays an essential role in inflammatory reaction and tumorigenesis.STAT3 has been established as a therapeutic target of various cancers including multiple myeloma,a hematological malignancy from plasma cells.Some STAT3 inhibitors have been developed and extensively studied.In this article, we review the roles of STAT3 in multiple myeloma.The advances and strategies in the development of STAT3 inhibitors are also being discussed.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号